Role of pegylated liposomal doxorubicin in ovarian cancer
- 31 January 2005
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 96 (1) , 10-18
- https://doi.org/10.1016/j.ygyno.2004.09.046
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- 157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancerEuropean Journal of Cancer Supplements, 2003
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2000
- Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.Journal of Clinical Oncology, 1998
- Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1998
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997